JPRN-UMIN000026143
Recruiting
Phase 2
Phase 2 study of dose-dense nab-paclitaxel followed by EC as neoadjuvant chemotherapy for HER2-negative breast cancer - Phase 2 study of dose-dense nab-paclitaxel followed by EC as neoadjuvant chemotherapy for HER2-negative breast cancer
Teikyo University School of Medicine0 sites50 target enrollmentFebruary 20, 2017
ConditionsHER2-negative primary breast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- HER2-negative primary breast cancer
- Sponsor
- Teikyo University School of Medicine
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Women who are pregnant or lactating 2\) Multiple primary cancer 3\) HER2\-positive breast cancer 4\) Poorly controlled complication (interstitial pneumonia, severe diabetes, heart failure, renal insufficiency, hepatic insufficiency) 5\) Active infection 6\) Serious peripheral neuropathy (\>\=CTCAE grade2\) 7\) Ineligible based on decision of an investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
A phase II study of low dose nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancerunresectable or recurrent gastric canceJPRN-UMIN000016196Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine37
Completed
Phase 2
Phase II study of low-dose Nab-paclitaxel for advanced breast cancerJPRN-UMIN000012048Kitasato University Kitasato Institute Hospital20
Completed
Not Applicable
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
Completed
Phase 2
A phase 2 study of weekly Nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancerBreast cancerJPRN-UMIN000007510ahanishi Clinic30
Recruiting
Not Applicable
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast CancerBreast cancerJPRN-UMIN000005979Wakayama Medical University50